Veracyte Inc (NASDAQ:VCYT) Short Interest Decreased By 0.67%

March 14, 2018 - By Adrian Erickson

 Veracyte Inc (NASDAQ:VCYT) Short Interest Decreased By 0.67%

Investors sentiment decreased to 1.76 in 2017 Q3. Its down 0.12, from 1.88 in 2017Q2. It worsened, as 11 investors sold Veracyte, Inc. shares while 14 reduced holdings. 14 funds opened positions while 30 raised stakes. 22.46 million shares or 6.26% more from 21.14 million shares in 2017Q2 were reported.
Goldman Sachs Group Inc reported 29,084 shares or 0% of all its holdings. Fincl Bank Of Montreal Can has 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 15,398 shares. Boston Advsr Ltd Limited Liability Company invested in 0.01% or 58,910 shares. Invesco Ltd reported 11,336 shares. Millennium Limited Liability Company holds 757,681 shares or 0.01% of its portfolio. Federated Investors Pa accumulated 0.01% or 525,000 shares. Ajo Lp stated it has 53,663 shares or 0% of all its holdings. Ascend Capital Ltd Limited Liability Company has 0.04% invested in Veracyte, Inc. (NASDAQ:VCYT). Northern, a Illinois-based fund reported 274,294 shares. Broadfin Cap Ltd Com reported 1.32% stake. State Of Wisconsin Investment Board owns 17,000 shares or 0% of their US portfolio. Rhumbline Advisers owns 25,119 shares or 0% of their US portfolio. Quantum holds 51,055 shares or 0.11% of its portfolio. Geode Mgmt Lc accumulated 156,423 shares. One Trading Lp reported 3,189 shares.

Since September 25, 2017, it had 0 insider buys, and 3 sales for $381,180 activity. 20,000 Veracyte, Inc. (NASDAQ:VCYT) shares with value of $180,000 were sold by Hall Christopher M.

The stock of Veracyte Inc (NASDAQ:VCYT) registered a decrease of 0.67% in short interest. VCYT’s total short interest was 737,500 shares in March as published by FINRA. Its down 0.67% from 742,500 shares, reported previously. With 131,400 shares average volume, it will take short sellers 6 days to cover their VCYT’s short positions. The short interest to Veracyte Inc’s float is 3.54%.

The stock decreased 2.35% or $0.15 during the last trading session, reaching $6.24. About 71,260 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has risen 56.46% since March 14, 2017 and is uptrending. It has outperformed by 39.76% the S&P500.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $213.98 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Among 6 analysts covering Veracyte (NASDAQ:VCYT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Veracyte had 11 analyst reports since August 14, 2015 according to SRatingsIntel. As per Tuesday, November 7, the company rating was downgraded by Janney Capital. As per Friday, August 14, the company rating was maintained by BTIG Research. The firm earned “Buy” rating on Tuesday, November 29 by Janney Capital. Piper Jaffray downgraded Veracyte, Inc. (NASDAQ:VCYT) on Tuesday, November 7 to “Hold” rating. Cantor Fitzgerald initiated the stock with “Buy” rating in Friday, December 18 report. The rating was maintained by Leerink Swann on Tuesday, November 7 with “Outperform”. The stock has “Overweight” rating by Piper Jaffray on Friday, August 14.

More news for Veracyte, Inc. (NASDAQ:VCYT) were recently published by:, which released: “Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma …” on March 14, 2018.‘s article titled: “Form 4 VERACYTE, INC. For: Mar 02 Filed by: Hall Christopher M” and published on March 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: